{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.53","upperLimit":"7.59","value":"5.82"},{"groupId":"OG001","lowerLimit":"3.19","upperLimit":"5.16","value":"3.98"},{"groupId":"OG002","lowerLimit":"3.58","upperLimit":"5.59","value":"4.70"},{"groupId":"OG003","lowerLimit":"3.71","upperLimit":"5.75","value":"4.57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"108"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"111"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the period from study entry until disease progression, death, or the last date of contact. Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.\n\nCisplatin: Given IV\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Paclitaxel, Cisplatin)"},{"description":"Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.\n\nCisplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nVinorelbine Tartrate: Given IV","id":"OG001","title":"Arm II (Vinorelbine, Cisplatin)"},{"description":"Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.\n\nCisplatin: Given IV\n\nGemcitabine Hydrochloride\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Gemcitabine, Cisplatin)"},{"description":"Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.\n\nCisplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nTopotecan Hydrochloride: Given IV","id":"OG003","title":"Arm IV (Topotecan, Cisplatin)"}],"paramType":"MEDIAN","populationDescription":"Evaluable (treatment)","reportingStatus":"POSTED","timeFrame":"Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)","title":"Duration of Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}